AC Immune Ownership
| ACIU Stock | USD 3.40 0.01 0.29% |
Shares in Circulation | First Issued 2015-03-31 | Previous Quarter 99.7 M | Current Value 100.9 M | Avarage Shares Outstanding 70.7 M | Quarterly Volatility 13.8 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
ACIU |
ACIU Stock Ownership Analysis
About 22.0% of the company shares are held by company insiders. The book value of AC Immune was presently reported as 1.3. The company recorded a loss per share of 0.45. AC Immune had not issued any dividends in recent years. AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland. AC Immune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. For more info on AC Immune please contact Andrea Pfeifer at 41 21 345 91 21 or go to https://www.acimmune.com.Besides selling stocks to institutional investors, AC Immune also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different AC Immune's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align AC Immune's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
AC Immune Quarterly Liabilities And Stockholders Equity |
|
About 22.0% of AC Immune are currently held by insiders. Unlike AC Immune's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against AC Immune's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of AC Immune's insider trades
ACIU Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as AC Immune is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading AC Immune backward and forwards among themselves. AC Immune's institutional investor refers to the entity that pools money to purchase AC Immune's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Eversept Partners, Llc | 2024-09-30 | 99.3 K | Alps Advisors Inc | 2024-09-30 | 76.6 K | Geode Capital Management, Llc | 2024-09-30 | 58.3 K | Two Sigma Investments Llc | 2024-09-30 | 57.3 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 57.1 K | Man Group Plc | 2024-09-30 | 27.4 K | Citadel Advisors Llc | 2024-09-30 | 21.8 K | Nomura Holdings Inc | 2024-06-30 | 20 K | Group One Trading, Lp | 2024-06-30 | 19.4 K | Bvf Inc | 2024-09-30 | 19.5 M | Blackrock Inc | 2024-06-30 | 2.6 M |
AC Immune Outstanding Bonds
AC Immune issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. AC Immune uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ACIU bonds can be classified according to their maturity, which is the date when AC Immune has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
AC Immune Corporate Filings
6K | 14th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 26th of July 2024 Other Reports | ViewVerify | |
| 14th of March 2024 Other Reports | ViewVerify | |
13A | 9th of February 2024 An amended filing to the original Schedule 13G | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ACIU Stock Analysis
When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.